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Objectives: To determine protease mutations that develop at viral failure for protease inhibitor (PI)-naive patients
on a regimen containing the PI atazanavir.
Methods: Resistance tests on patients failing atazanavir, conducted as part of routine clinical care in a multicentre
observational study, were randomly matched by subtype to resistance tests from PI-naive controls to account for
natural polymorphisms. Mutations from the consensus B sequence across the protease region were analysed for
association and defined using the IAS-USA 2011 classification list.
Results: Four hundred and five of 2528 (16%) patients failed therapy containing atazanavir as a first PI over a
median (IQR) follow-up of 1.76 (0.84–3.15) years and 322 resistance tests were available for analysis. Recognized
major atazanavir mutations were found in six atazanavir-experienced patients (P,0.001), including I50L and
N88S. The minor mutations most strongly associated with atazanavir experience were M36I, M46I, F53L, A71V,
V82T and I85V (P,0.05). Multiple novel mutations, I15S, L19T, K43T, L63P/V, K70Q, V77I and L89I/T/V, were
also associated with atazanavir experience.
Conclusions: Viral failure on atazanavir-containing regimens was not common and major resistance mutations
were rare, suggesting that adherence may be a major contributor to viral failure. Novel mutations were described
that have not been previously documented.
Keywords: HIV, drug resistance mutations, naive patients, protease inhibitors, virological failure
Introduction
Since the approval of the protease inhibitor (PI) atazanavir by the
FDA (and ‘positive opinion’ by the European Medicines Agency) in
2003 it has become a widely used third agent in combination
antiretroviral therapy (ART) and is recommended as a possible
component of first-line therapy in national and international
HIV treatment guidelines.1,2 Previous research investigating
the development of drug resistance to atazanavir in a non-
randomized controlled trial setting is limited by its focus on
patients with prior PI exposure3,4 or the development of major
PI mutations.5 Randomized controlled trials6,7 have shown that
the key substitutions in patients failing atazanavir-containing
regimens are I50L and N88S.7 This study examines patterns of
resistance to atazanavir in a large clinical cohort of patients
with no prior PI exposure.
Methods
Genotypic resistance test results of population sequencing of the pol gene
were obtained from the UK HIV Drug Resistance Database (UKHDRD)8 and
linked to pseudo-anonymized clinical information from the UK Collabora-
tive HIV Cohort Study (UK CHIC).9 The UKHDRD and UK CHIC were estab-
lished in 2001 and collect, respectively, all resistance tests conducted at
public laboratories within the UK as part of routine clinical care, and clinical
information routinely collected on HIV-positive individuals aged over
16 years who have attended one of the 15 collaborating centres for care
at any time from 1996.
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Patients who were PI naive, regardless of other ARTexperience, and who
were initiated on a regimen containing atazanavir between 2001 and 2010
were included for analysis in the study. Virological failure was defined as:
(i) two consecutive viral loads.1000 copies/mL after previous suppression
(≤400 copies/mL); (ii) one viral load .1000 copies/mL after previous
suppression followed by a treatment change; or (iii) one viral load
.1000 copies/mL after 180 days on ART without suppression. Valid resist-
ance tests were samples taken after at least 30 days of atazanavir treat-
ment and within 30 days of discontinuing the drug. Where more than
one resistance test was available for a patient, the latest test was selected
for analysis. For each index resistance test we attempted to select at
random 10 resistance tests from ART-experienced, PI-naive patients with
the same viral subtype as controls for variation in background polymorph-
isms. When fewer than 10 such tests could be identified they were supple-
mented by tests from ART-naive patients with the same viral subtype. For
rare subtypes such as CRF11 and CRF13 (where CRFstands for circulating re-
combinant form), sufficient control samples to match in a 1:10 ratio were
not available. Apart from these factors, control samples were selected sto-
chastically and no other demographic information was used in the process.
Protease mutations were categorized based on the IAS-USA 2011 mu-
tation list as either major or minor atazanavir mutations.10 The prevalence
of each amino acid substitution was compared between index and control
resistance tests using Fisher’s exact test. Mutations are reported if they are:
(i) classified as a major atazanavir mutation or (ii) observed in at least two
index resistance tests and with a significantly (P,0.05) higher frequency
compared with control tests. Subtype was inferred from the pol sequence
using the REGA subtyping algorithm.11 No adjustments were made for
the multiple hypothesis tests performed, on the basis that this is an explora-
toryanalysis to identify associations to be verified in other datasets. All ana-
lyses were conducted in Stata/IC 12.1 software (StataCorp LP, College
Station, TX, USA).
Results
A total of 2865 patients used atazanavir as their first PI, and of
these, 2528 (88%) had sufficient viral load data for the determin-
ation of virological failure status, with a median (Q1–Q3) follow-up
of 1.76 (0.84–3.15) years. Four hundred and five (16%) patients
experienced virological failure, of whom 322 (80%) had one or
more valid resistance tests (total of 455 tests).
Patient characteristics relating to the index and control resist-
ance tests are shown in Table 1. Among index patients, atazanavir
was typically boosted with ritonavir (n¼251; 78%) and used in
combination with two or more nucleos(t)ide reverse transcriptase
inhibitors (NRTIs) (n¼294; 91%). Common NRTI drugs for those on
boosted atazanavir included tenofovir (n¼207; 82%), emtricita-
bine (n¼131; 52%), lamivudine (n¼68; 27%), abacavir (n¼55;
22%) and zidovudine (n¼25; 10%). Those patients on unboosted
atazanavir typically had tenofovir (n¼46; 65%), emtricitabine
(n¼26; 37%), lamivudine (n¼27; 38%), abacavir (n¼16; 23%)
and zidovudine (n¼14; 20%) as part of their NRTI backbone. The
median (Q1–Q3) time on atazanavir at the time of resistance sam-
pling was 1.28 (0.49–2.73) years and the median (Q1–Q3) time on
ART was 2.80 (1.00–5.87) years. Atazanavir was a component of
the initial combination ART regimen for 117 (36.3%) patients; for
the remainder it was first used in the second-line or subsequent
regimen.
Only 6 (1.9%) index patients experiencing virological failure had
a major atazanavir-associated mutation, all in isolation: I50L
(n¼3), I84V (n¼2) and N88S (n¼1) (Table 2). However, I84V was
also observed in 0.32% of control samples, indicating that it
cannot necessarily be concluded that it was directly selected by
atazanavir. Only 6 of 49 recognized minor atazanavir-associated
mutations were significantly associated with atazanavir exposure,
although many of these are expected to be selected only as com-
pensatory mutations. The remaining 43 minor atazanavir muta-
tions were either not detected in this dataset (L10C, K20V, E34Q,
F53Y, I54L/M/T/A, A71L, G73C/T, V82Fand I93M) or were not signifi-
cantly associated with atazanavir exposure (L10I/F/V, G16E, K20R/
M/I/T, L24I, V32I, L33I/F/V, M36L/V, M46L, G48V, I54V, D60E, I62V,
I64L/M/V, A71I/T, G73S/A, V82A/I, L90M and I93L). Nine other
mutations at six codons (15, 19, 43, 63, 70 and 89) not currently
recognized as being associated with atazanavir were significantly
more frequent in the index resistance tests compared with the
control tests. This included three different substitutions (I, T and
V) at codon 89. There was no evidence of a difference between
ritonavir-boosted atazanavirand unboosted therapy in terms of in-
dividual mutations or in the number of mutations selected (data
not shown).
Conclusive evidence that a mutation was directly selected by
atazanavir in an individual patient requires demonstration of its
absence in a baseline resistance test. However, a baseline test
was available in only 137/322 (43%) index patients, limiting the
value of this approach. Specifically, none of the patients who
were observed to have I15S, K43T, I50L, V82T, I84V, N88S or
L89V mutations at virological failure had a baseline resistance
test. In almost all patients in whom a baseline resistance test
was available, the common M36I and L63P polymorphisms pre-
existed prior to exposure to atazanavir.
Discussion
Our findings show that very few patients failing a therapy contain-
ing atazanavir are likely to have developed one of the major prote-
ase resistance mutations (I50L, I84V and N88S) that confer
high-level phenotypic resistance to this drug. However, there was
an increased frequency of several other mutations, including
I15S, L19T, K43T, L63P/V, K70Q and L89I/T/V, which are not recog-
nized to be associated with atazanavir by the most recent IAS clas-
sification. The finding of multiple amino acid substitutions at
codons 63 and 89 strengthens the likelihood that mutations at
these codons could play a role in atazanavir failure and suggests
that atazanavir-induced changes at these sites may have a struc-
tural impact on the protease enzyme. Two other mutations, K43T
and L89V, have previously been shown to decrease susceptibility to
PIs in combination with other mutations.12 The low frequency of
atazanavir-associated resistance mutations in those with viro-
logical failure suggests that most virological failures may have
been a consequence of suboptimal adherence rather than resist-
ance per se. Alternatively, it is possible that determinants of sus-
ceptibility to atazanavir lie outside the region of the genome that
is examined during routine resistance testing, so could not be
detected in this study.13
There are two main approaches to examining associations
between specific mutations and resistance to individual drugs
using clinical data. The first is to examine the effect on clinical re-
sponse of pre-existing mutations selected by prior exposure to
other drugs within that class. In the current context, Vora et al.14
studied 62 patients with prior PI exposure who took boosted ataza-
navir. They described eight mutations that had an adverse effect
on viral load reduction at 3 months, but only two of these (M46I
Dolling et al.
2340
and I84V) coincided with those identified in our analysis. The
second approach, the one adopted in the present paper, is to iden-
tify mutations that appear to have emerged under selective drug
pressure. Other cohort studies using this approach have tended
to focus on highly pre-treated patients, whose patterns of resist-
ance are likely to differ materially from those receiving the drug
as the first within that class.4,15 However, several patients in the
IMPACT study, which evaluated atazanavir-containing regimens,
were PI naive at enrolment.3 Although there was a high frequency
(7/39) of PI substitutions (including L33I/F and L90M, which we did
not observe) in this subgroup, many patients were on NRTI-sparing
dual-PI regimens and it is not possible to assess whether the
substitutions observed were selected by atazanavir or by the
other PI in the regimen.
Our study has several limitations. Despite the large sample of
patients who took atazanavir as their first PI, the fact that there
were relatively few treatment failures limits the power to detect
new resistance mutations. Also, resistance data were not available
for all treatment failures and baseline resistance tests were not
available for the majority of the subjects. Therefore, some of the
mutations detected may have pre-existed as polymorphisms or
transmitted mutations. Furthermore, bulk sequencing means
that some mutations may have existed as an undetectable minor-
ity population at baseline. Indeed, if these pre-existing polymorph-
isms/mutations reduced the susceptibility to atazanavir and
increased the likelihood of virological failure an association would
have been induced even if atazanavir did not select for this muta-
tion. Finally, as an exploratory analysis a large number of potential
Table 1. Characteristics of the study population
Atazanavir-experienced (index)
patients n¼322 PI-naive (control) patients n¼3209
n % n %
Gender
female 86 26.7 920 28.7
male 236 73.3 2289 71.3
Exposure source
homosexual/bisexual 158 49.1 1598 49.8
heterosexual 132 41.0 1238 38.6
other 20 6.2 129 4.0
unknown 12 3.7 244 7.6
Ethnicity
white 161 50.0 1621 50.5
black 114 35.4 1022 31.8
other 26 8.1 230 7.2
unknown 21 6.5 336 10.5
Subtype
A 21 6.5 210 6.5
B 179 55.6 1790 55.8
C 54 16.8 540 16.8
AE 5 1.6 50 1.6
AG 16 5.0 160 5.0
othera 16 5.0 149 4.6
unknown 31 9.6 310 9.7
Median Q1–Q3 Median Q1–Q3
Exposure to atazanavir (years) 1.28 0.49–2.73 NA NA
Time on ART (years)b 2.80 1.00–5.87 2.63 0.89–5.31
Age (years) 40.85 35.73–46.01 36.94 31.94–42.91
Year of resistance test 2008 2006–2009 2003 2000–2006
Baseline RNA (log10copies/mL) 4.59 3.75–5.17 4.40 3.51–5.06
Baseline CD4 (cells/mm3) 289 121–434 303 170–470
RNA at resistance sample (log10copies/mL) 3.36 2.59–4.47 4.20 3.41–4.90
CD4 at resistance sample (cells/mm3) 315 200–499 290 173–438
NA, not applicable.
aMatching not possible for rare CRFs such as CRF11 and CRF13.
bIn the control group, based on the 2467 (77%) ART-experienced patients.
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associations were analysed and some of the significant results
reported could be false positives.
Furtherresearchshouldcontinuetomonitordrugresistanceatviro-
logical failure in patients failing first-line atazanavir to assess whether
there is an accumulation of further accessory or compensatory muta-
tions in the absence of major resistance mutations. This could result in
a re-examination of the concept that atazanavir has a distinct resist-
ance profile with little cross-resistance to other PIs, and that these
can therefore be used effectively after failure on atazanavir.6
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